380P Tumour naïve circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

2022-09-01

Day, D.

Starus, A.

Lamik, A.

Sieber, O.

Begbie, S.

Bonaventura, A.

Rai, S.

Karanth, Narayan

Underhill, C.R.

Nott, L.M.

van Hazel, G.

van Hagen, T.

Wong, M.

Saqib, A.

Eastgate, M.

Srivastav, R.

Chia, J.

Toh, H.C.

Jones, F.

Segelov, E.

Conference abstract

Publication

Elsevier BV

Plasma ctDNA detects minimal residual disease (MRD) and is associated with disease recurrence in curatively treated CRC. In a randomised, double-blinded, phase III study (The ASpirin for Dukes C and high risk Dukes B COLorecTal cancer trial [ASCOLT], NCT00565708) evaluating the benefit of adjuvant aspirin, pts in the Australian and New Zealand cohort underwent prospective collection of plasma at baseline (within 90 days of completing adjuvant chemotherapy), 6 and 12 months, as well as surgical specimens. In a pilot cohort of 51 pts, we studied the utility of an ultra-sensitive ctDNA assay (SafeSEQ, Sysmex Inostics) for MRD detection.

link

Annals of Oncology 33:S710 DOI:10.1016/j.annonc.2022.07.518